Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16953418 | 0.86 | DAO (0.42) | DAOHTTALDH1A1MAOAMAOB | |
| SCHEMBL16105820 | 0.85 | DAO (0.55) | DAOHTTALDH1A1MAOAMAOB | |
| SCHEMBL6649880 | 0.85 | DAO (0.41) | DAOHTTALDH1A1MAOAMAOB | |
| SCHEMBL9579438 | 0.83 | DAO (0.40) | DAOHTTALDH1A1MAOAMAOB | |
| SCHEMBL10823078 | 0.80 | PNMT (0.45) | TAAR1 | |
| SCHEMBL8084327 | 0.80 | KDM1A (0.35) | DAOTAAR1KDM1A | |
| SCHEMBL15517152 | 0.80 | DAO (0.45) | DAOHTTALDH1A1MAOBTAAR1 | |
| SCHEMBL126440 | 0.80 | HTT (0.45) | DAOHTTALDH1A1MAOAMAOB | |
| SCHEMBL631580 | 0.78 | TAAR1 (0.58) | DAOALDH1A1MAOBTAAR1 | |
| SCHEMBL3246622 | 0.78 | DAO (0.46) | DAOHTTALDH1A1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102656163-B | Suppress the heterogeneous ring compound of PASK | BIOENERGENIX (US) | 2016-01-13 | — | — | CN | claimed |
| CN-103459382-A | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC | 2013-12-18 | — | — | CN | claimed |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-12-18 | — | — | US | claimed |
| US-11118072-B2 | Water repellent film-forming composition and water repellent film | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| EP-3553121-B1 | WATER REPELLENT FILM-FORMING COMPOSITION AND WATER REPELLENT FILM | SHINETSU CHEMICAL CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-110358445-A | Water repellent film, which is formed, uses composition and water repellent film | 信越化学工业株式会社 | 2019-10-22 | — | — | CN | disclosed |
| US-20190315972-A1 | WATER REPELLENT FILM-FORMING COMPOSITION AND WATER REPELLENT FILM | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3553121-A1 | WATER REPELLENT FILM-FORMING COMPOSITION AND WATER REPELLENT FILM | Shin-Etsu Chemical Co., Ltd. (JP) | 2019-10-16 | — | — | EP | disclosed |
| CN-107141313-A | Transparent oxide electrode and its production method that surface modifier, surface for transparent oxide electrode are modified | 信越化学工业株式会社 | 2017-09-08 | — | — | CN | disclosed |
| CN-102656163-B | Suppress the heterogeneous ring compound of PASK | BIOENERGENIX (US) | 2016-01-13 | — | — | CN | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-103848859-A | Surface modifier for transparent oxide electrode, surface-modified transparent oxide electrode, and method for producing same | SHINETSU CHEMICAL CO | 2014-06-11 | — | — | CN | disclosed |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-0880524-B1 | ADENOSIN ANTAGONISTS, METHOD OF PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-19 | — | — | EP | disclosed |
| EP-0978517-A2 | Triazolopurines, process for their preparation and their use as medicaments | Boehringer Ingelheim Pharma KG (DE) | 2000-02-09 | — | — | EP | disclosed |
| EP-0880524-A1 | NEW TRIAZOLOPURINES, METHOD OF PREPARING THEM AND THEIR USE AS DRUGS | Boehringer Ingelheim Pharma KG (DE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998003511-A1 | NEW TRIAZOLOPURINES, METHOD OF PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | CXCR2, BICRA, CXCR1 | DAO 3672/4885HTT 1512/4885ALDH1A1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.